Successful Transport of Blood Samples with Small Drones
|
By LabMedica International staff writers Posted on 17 Aug 2015 |

Image: Preparation of clinical blood samples for test-flights by small drone. (1) Left: Custom-cut foam block. (2) Right: Placement of sealed foam lock in the bio-hazard bags as well as absorbent material for potential sample containment (Photos courtesy of Johns Hopkins Medicine and PLOS One).

Image: (3) Left: Placement of first bio-hazard bag inside the second bio-hazard bag. (4) Middle-right: Placement of double-wrapped payload in the fuselage (Photo courtesy of Johns Hopkins Medicine and PLOS One).

Image: (5) Left: Covered, secured, and labeled fuselage. (6) Right: Launch with hand toss (Photo courtesy of Johns Hopkins Medicine and PLOS One).
A proof-of-concept, initial study has shown that small unmanned aerial systems (UAS) could potentially be used to transport clinical blood specimens for diagnostics without damage to the specimens.
In a first rigorous examination published about the impact of drone transport on biological samples, a team of clinical researchers and engineers, led by Timothy Kien Amukele, MD, PhD, pathologist at Johns Hopkins University School of Medicine (Baltimore, MD, USA) and director of a collaboration with Makerere University in Uganda, found that results of common, routine tests on the blood samples were not affected by up to 40 minutes of sample-travel in hobby-sized drones. This could especially aid millions of people in developing nations where most tests are currently done by dedicated laboratories that can be scores of miles from remote clinics in rural and economically impoverished areas that lack, for example, good roads.
“Biological samples can be very sensitive and fragile,” said Dr. Amukele. That sensitivity makes even the pneumatic-tube systems used by many hospitals, for example, unsuitable for transporting blood for certain purposes. Of particular concern related to sample transport in drones is the sudden acceleration that marks the launch of the vehicle and the jostling when the drone lands on its belly. “Such movements could have destroyed blood cells or prompted blood to coagulate and I thought all kinds of blood tests might be affected, but our study shows they weren’t,” he added.
For the study, total of 6 blood samples were collected from each of 56 healthy adult volunteers at Johns Hopkins Hospital. Samples were driven to a flight site an hour’s drive from the hospital on days when the temperature was moderate. There, half the samples were held stationary (non-flight); the other half were packaged for protection during the in-flight environment and to prevent leakage, then loaded into a hand-launched fixed-wing drone and flown for periods of 6–38 minutes. Owing to Federal Aviation Administration (FAA) rules, the flights were conducted in an unpopulated area, kept below 100 meters and in the line-of-sight of the certified drone pilot.
Samples were driven back from the flight-field to the Johns Hopkins Hospital Core Laboratory, where 33 of the most common chemistry, hematology, and coagulation tests were performed (tests that together account for around 80% of all such tests performed), including for sodium, glucose, and red blood cell count.
Comparing lab results of the flown vs. non-flown samples from each volunteer showed that these flights essentially had no impact, although the precision of one blood test—for total carbon dioxide (the bicarbonate test)—did differ for some samples pairs. This may be because the blood sat for up to 8 hours before being tested, but whether the out-of-range results were due to this time lag or to the drone transport is unknown. Nevertheless, there were no consistent differences in results between the flown vs. non-flown blood.
“The ideal way to test that would be to fly the blood around immediately after drawing it, but neither the FAA nor Johns Hopkins would like drones flying around the hospital,” said Dr. Amukele.
The likely next step is a pilot study in Africa where clinics are sometimes 60 or more miles away from labs. “A drone could go 100 km in 40 minutes,” said Dr. Amukele, “They’re less expensive than motorcycles, are not subject to traffic delays, and the technology already exists for the drone to be programmed to “home” to certain GPS coordinates, like a carrier pigeon.”
Drones have already been tested as carriers of medicines to clinics in remote areas, but whether and how drones will be used to carry medicines and potentially infectious patient specimens over more populated areas will depend on laws and regulations.
The study, by Amukele TK, et al, was published July 29, 2015, in the journal PLOS One.
Related Links:
Johns Hopkins University School of Medicine
In a first rigorous examination published about the impact of drone transport on biological samples, a team of clinical researchers and engineers, led by Timothy Kien Amukele, MD, PhD, pathologist at Johns Hopkins University School of Medicine (Baltimore, MD, USA) and director of a collaboration with Makerere University in Uganda, found that results of common, routine tests on the blood samples were not affected by up to 40 minutes of sample-travel in hobby-sized drones. This could especially aid millions of people in developing nations where most tests are currently done by dedicated laboratories that can be scores of miles from remote clinics in rural and economically impoverished areas that lack, for example, good roads.
“Biological samples can be very sensitive and fragile,” said Dr. Amukele. That sensitivity makes even the pneumatic-tube systems used by many hospitals, for example, unsuitable for transporting blood for certain purposes. Of particular concern related to sample transport in drones is the sudden acceleration that marks the launch of the vehicle and the jostling when the drone lands on its belly. “Such movements could have destroyed blood cells or prompted blood to coagulate and I thought all kinds of blood tests might be affected, but our study shows they weren’t,” he added.
For the study, total of 6 blood samples were collected from each of 56 healthy adult volunteers at Johns Hopkins Hospital. Samples were driven to a flight site an hour’s drive from the hospital on days when the temperature was moderate. There, half the samples were held stationary (non-flight); the other half were packaged for protection during the in-flight environment and to prevent leakage, then loaded into a hand-launched fixed-wing drone and flown for periods of 6–38 minutes. Owing to Federal Aviation Administration (FAA) rules, the flights were conducted in an unpopulated area, kept below 100 meters and in the line-of-sight of the certified drone pilot.
Samples were driven back from the flight-field to the Johns Hopkins Hospital Core Laboratory, where 33 of the most common chemistry, hematology, and coagulation tests were performed (tests that together account for around 80% of all such tests performed), including for sodium, glucose, and red blood cell count.
Comparing lab results of the flown vs. non-flown samples from each volunteer showed that these flights essentially had no impact, although the precision of one blood test—for total carbon dioxide (the bicarbonate test)—did differ for some samples pairs. This may be because the blood sat for up to 8 hours before being tested, but whether the out-of-range results were due to this time lag or to the drone transport is unknown. Nevertheless, there were no consistent differences in results between the flown vs. non-flown blood.
“The ideal way to test that would be to fly the blood around immediately after drawing it, but neither the FAA nor Johns Hopkins would like drones flying around the hospital,” said Dr. Amukele.
The likely next step is a pilot study in Africa where clinics are sometimes 60 or more miles away from labs. “A drone could go 100 km in 40 minutes,” said Dr. Amukele, “They’re less expensive than motorcycles, are not subject to traffic delays, and the technology already exists for the drone to be programmed to “home” to certain GPS coordinates, like a carrier pigeon.”
Drones have already been tested as carriers of medicines to clinics in remote areas, but whether and how drones will be used to carry medicines and potentially infectious patient specimens over more populated areas will depend on laws and regulations.
The study, by Amukele TK, et al, was published July 29, 2015, in the journal PLOS One.
Related Links:
Johns Hopkins University School of Medicine
Latest Hematology News
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Channels
Clinical Chemistry
view channel
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read more
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreMolecular Diagnostics
view channel
DNA Aptamers Offer New Tool for Easy Alzheimer's Blood Test
Alzheimer’s disease is the most common cause of dementia and is marked by progressive loss of nerve cells that begins many years before symptoms become noticeable. Detecting early signs of neurodegeneration... Read more
Jumping "DNA Parasites” Linked to Early Tumor Development
Cancer genomes accumulate complex structural variants that can be difficult to resolve with standard short-read sequencing, obscuring clinically relevant drivers of disease. Transposable elements, particularly... Read more
AI-Based Liquid Biopsy Detects Liver Fibrosis, Cirrhosis and Chronic Disease Signals
Liver fibrosis and cirrhosis often develop silently for years before symptoms appear, making early diagnosis difficult. Detecting these conditions earlier could allow treatment before irreversible damage... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreIndustry
view channel
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more








